NEULAND LAB LTD. (NEULANDLAB) financials

NEULAND LAB LTD. (NEULANDLAB) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Market Cap: ₹25,243Cr.
Current Price: ₹19,675
Stock P/E: 50.8
ROE: 21.3%
ROCE: 26.5%
Book Value: ₹1,454
Dividend Yield: 0.17%
52W High / Low: ₹24,235/11,500

In Jun 2026, NEULAND LAB LTD. (NEULANDLAB) reported sales ₹642 Cr and net profit ₹147 Cr.

Annual TTM: sales ₹2,372 Cr, net profit ₹497 Cr.

Shareholding: Promoters 32.26% (Sep 2026), FIIs 21.93% (Sep 2026), DIIs 16.25% (Sep 2026), Government 0.00% (Sep 2026), Public 29.55% (Sep 2026).

NEULANDLAB quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	311	398	328	293	514	440	776	642
Expenses	250	312	278	258	359	363	469	419
Operating Profit	61	86	51	34	155	77	307	223
OPM %	20%	22%	15%	12%	30%	18%	40%	35%
Other Income	4	60	7	8	2	8	12	8
Interest	1	2	2	5	5	7	7	7
Depreciation	16	16	17	20	23	24	25	27
Profit before tax	49	128	39	17	129	54	287	198
Tax %	34%	20%	29%	21%	25%	26%	26%	25%
Net Profit	32	101	28	14	96	40	213	147
EPS in Rs	24.91	79.03	21.61	10.69	75.18	31.50	165.64	114.86
Raw PDF	—	—	—	—	—	—	—	—

NEULANDLAB profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	763	937	951	1,191	1,559	1,477	2,023	2,372
Expenses	661	790	807	919	1,096	1,147	1,444	1,610
Operating Profit	101	147	144	272	462	330	579	762
OPM %	13%	16%	15%	23%	30%	22%	29%	32%
Other Income	4	16	0	9	12	90	25	31
Interest	22	18	13	13	14	8	24	26
Depreciation	31	40	49	53	60	66	92	98
Profit before tax	52	105	82	215	401	345	488	668
Tax %	70%	23%	22%	24%	25%	25%	26%	—
Net Profit	16	80	64	163	300	259	363	497
EPS in Rs	12.38	62.58	49.52	127.14	233.52	202.21	283.02	387.18
Dividend Payout %	16%	8%	10%	8%	6%	6%	12%	—

NEULANDLAB balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13	13	13	13	13
Reserves	683	693	769	823	975	1,264	1,505	1,853
Borrowings	231	264	182	241	128	95	157	301
Other Liabilities	203	260	359	306	463	459	503	761
Total Liabilities	1,130	1,230	1,324	1,382	1,579	1,831	2,178	2,928
Fixed Assets	541	653	716	767	758	824	955	1,177
CWIP	104	24	17	20	41	46	48	211
Investments	8	8	7	4	1	1	109	2
Other Assets	476	545	583	590	781	960	1,066	1,539
Total Assets	1,130	1,230	1,324	1,382	1,579	1,831	2,178	2,928

NEULANDLAB cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	70	57	189	60	239	260	318	348
Cash from Investing Activity	-77	-49	-84	-96	-62	-150	-298	-424
Cash from Financing Activity	12	-5	-114	38	-136	-69	25	21
Net Cash Flow	4	2	-9	3	41	41	44	-55
Free Cash Flow	7	9	84	-37	174	118	112	-49
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	129%	60%	133%	56%	104%	80%	119%	78%

NEULANDLAB shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	32.68%	32.67%	32.67%	32.64%	32.63%	32.63%	32.62%	32.26%
FIIs	23.86%	22.12%	21.69%	20.60%	20.90%	20.46%	21.08%	21.93%
DIIs	9.09%	10.97%	11.57%	13.55%	14.72%	15.84%	16.52%	16.25%
Government	0.40%	0.40%	0.40%	0.40%	0.00%	0.00%	0.00%	0.00%
Public	33.96%	33.85%	33.67%	32.80%	31.76%	31.08%	29.79%	29.55%
No. of Shareholders	39,315	39,333	42,419	44,393	46,187	46,304	44,340	49,741

NEULANDLAB key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	90	91	85	90	111	87	78	98
Inventory Days	191	209	205	227	211	220	238	245
Days Payable	123	114	130	105	135	125	161	134
Cash Conversion Cycle	158	186	160	212	187	183	155	209
Working Capital Days	136	135	59	72	78	87	74	74
ROCE %	4%	8%	11%	10%	21%	33%	19%	27%

NEULANDLABUpdated 19 Oct 2026, 5:52

Neuland Lab Ltd.

NEULANDLABUpdated 19 Oct 2026, 5:52

Market Cap

₹25,243Cr.

Current Price

₹19,675

High / Low

₹24,235/11,500

Stock P/E

50.8

ROE21.3%

ROCE26.5%

Book Value₹1,454

Face Value₹10.0

Dividend Yield0.17%

About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	363	2	266	2	14	84	25	62	48.5
Sep 2023	418	4	280	3	15	121	27	89	69.42
Dec 2023	393	4	272	2	15	104	22	81	62.9
Mar 2024	385	4	278	5	16	92	27	68	52.7
Jun 2024	440	3	316	25	16	130	25	98	76.65
Sep 2024	311	1	250	4	16	49	34	32	24.91
Dec 2024	398	2	312	60	16	128	20	101	79.03
Mar 2025	328	2	278	7	17	39	29	28	21.61
Jun 2025	293	5	258	8	20	17	21	14	10.69
Sep 2025	514	5	359	2	23	129	25	96	75.18
Dec 2025	440	7	363	8	24	54	26	40	31.5
Mar 2026	776	7	469	12	25	287	26	213	165.64
Jun 2026	642	7	419	8	27	198	25	147	114.86

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	469	27	402	0	15	24	36	16	17.76
Mar 2016	510	24	430	2	16	41	36	26	29.73
Mar 2017	579	21	473	1	19	67	30	46	52.2
Mar 2018	527	19	477	4	22	14	13	12	13.29
Mar 2019	667	16	609	3	26	20	19	16	12.58
Mar 2020	763	22	661	4	31	52	70	16	12.38
Mar 2021	937	18	790	16	40	105	23	80	62.58
Mar 2022	951	13	807	0	49	82	22	64	49.52
Mar 2023	1191	13	919	9	53	215	24	163	127.14
Mar 2024	1559	14	1096	12	60	401	25	300	233.52
Mar 2025	1477	8	1147	90	66	345	25	259	202.21
Mar 2026	2023	24	1444	25	92	488	26	363	283.02
TTM	2372	26	1610	31	98	668	—	497	387.18

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	32.26%
FIIs	21.93%
DIIs	16.25%
Public	29.55%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	32.8%	22.69%	6.02%	0.4%	38.1%
Mar 2024	32.74%	24.43%	6.54%	0.4%	35.88%
Jun 2024	32.72%	25.72%	6.39%	0.4%	34.77%
Sep 2024	32.64%	26.46%	6.38%	0.4%	34.12%
Dec 2024	32.68%	23.86%	9.09%	0.4%	33.96%
Mar 2025	32.67%	22.12%	10.97%	0.4%	33.85%
Jun 2025	32.67%	21.69%	11.57%	0.4%	33.67%
Sep 2025	32.64%	20.6%	13.55%	0.4%	32.8%
Dec 2025	32.63%	20.9%	14.72%	0%	31.76%
Mar 2026	32.63%	20.46%	15.84%	0%	31.08%
Jun 2026	32.62%	21.08%	16.52%	0%	29.79%
Sep 2026	32.26%	21.93%	16.25%	0%	29.55%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	9	151	188	164	511	123	41	8	339	511
Mar 2016	9	175	182	157	523	139	40	8	337	523
Mar 2017	9	534	192	150	885	466	20	8	392	885
Mar 2018	9	546	319	197	1071	475	126	8	462	1071
Mar 2019	13	683	231	203	1130	541	104	8	476	1130
Mar 2020	13	693	264	260	1230	653	24	8	545	1230
Mar 2021	13	769	182	359	1324	716	17	7	583	1324
Mar 2022	13	823	241	306	1382	767	20	4	590	1382
Mar 2023	13	975	128	463	1579	758	41	1	781	1579
Mar 2024	13	1264	95	459	1831	824	46	1	960	1831
Mar 2025	13	1505	157	503	2178	955	48	109	1066	2178
Mar 2026	13	1853	301	761	2928	1177	211	2	1539	2928

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	13	-14	1	0
Mar 2016	45	-20	-24	1
Mar 2017	39	-42	0	-3
Mar 2018	12	-116	105	0
Mar 2019	70	-77	12	4
Mar 2020	57	-49	-5	2
Mar 2021	189	-84	-114	-9
Mar 2022	60	-96	38	3
Mar 2023	239	-62	-136	41
Mar 2024	260	-150	-69	41
Mar 2025	318	-298	25	44
Mar 2026	348	-424	21	-55

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	100	85	114	134	90	91	85	90	111	87	78	98
Inventory Days	170	182	188	268	191	209	205	227	211	220	238	245
Days Payable	167	124	123	198	123	114	130	105	135	125	161	134
Cash Conversion Cycle	103	144	179	205	158	186	160	212	187	183	155	209
Working Capital Days	9	24	42	36	136	135	59	72	78	87	74	74
ROCE %	16%	18%	16%	4%	4%	8%	11%	10%	21%	33%	19%	27%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of NEULAND LAB LTD. (NEULANDLAB)?

The reported market capitalisation for NEULAND LAB LTD. (NEULANDLAB) is ₹25,243Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of NEULANDLAB?

The current price shown for NEULAND LAB LTD. (NEULANDLAB) on Fincrux is ₹19,675 with a 52-week high/low of ₹24,235/11,500.

What is the P/E ratio of NEULAND LAB LTD. (NEULANDLAB)?

The stock P/E for NEULAND LAB LTD. (NEULANDLAB) is 50.8 on Fincrux, with ROE at 21.3% and ROCE at 26.5%.

What were NEULANDLAB latest quarterly results?

For Jun 2026, NEULAND LAB LTD. (NEULANDLAB) reported sales ₹642 Cr and net profit ₹147 Cr (figures in ₹ crore unless noted).

What are NEULANDLAB annual sales and net profit?

For TTM, NEULAND LAB LTD. (NEULANDLAB) shows sales of ₹2,372 Cr and net profit of ₹497 Cr on the Fincrux profit & loss statement.

Who owns NEULAND LAB LTD. (NEULANDLAB)?

Latest shareholding for NEULAND LAB LTD. (NEULANDLAB) on Fincrux: Promoters 32.26% (Sep 2026), FIIs 21.93% (Sep 2026), DIIs 16.25% (Sep 2026), Government 0.00% (Sep 2026), Public 29.55% (Sep 2026).

Where can I find NEULAND LAB LTD. (NEULANDLAB) financials?

NEULAND LAB LTD. (NEULANDLAB) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show NEULANDLAB balance sheet and cash flow?

Yes. The NEULAND LAB LTD. (NEULANDLAB) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 5:52